Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib

Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer (ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this study was to explore whether the neutrophil-to-lymphocyte ratio (NLR) can be a tumor marker for ATC treated with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:In Vivo
Glavni autori: FUKUDA, NAOKI, TODA, KAZUHISA, FUJIWARA, YU, WANG, XIAOFEI, OHMOTO, AKIHIRO, URASAKI, TETSUYA, HAYASHI, NAOMI, SATO, YASUYOSHI, NAKANO, KENJI, YUNOKAWA, MAYU, ONO, MAKIKO, TOMOMATSU, JUNICHI, MITANI, HIROKI, TAKAHASHI, SHUNJI
Format: Artigo
Jezik:Inglês
Izdano: International Institute of Anticancer Research 2020
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7652499/
https://ncbi.nlm.nih.gov/pubmed/32871825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12113
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items